STOCK TITAN

Evaxion Biotech A/S American Depositary Share - EVAX STOCK NEWS

Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.

Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.

Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.

The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.

Recent news highlights key company activities, such as:

  • A replay of the R&D Day presentations is available on the company's website.
  • Information about the EVX-01 Phase 2 clinical trial.
  • The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.

To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.

Rhea-AI Summary

Evaxion Biotech reported a successful follow-on public offering (FPO) of 3,942,856 ordinary shares, raising $24.9 million in net proceeds. The company announced a critical collaboration with Merck to evaluate its immunotherapy EVX-01 alongside KEYTRUDA® in a Phase 2b clinical trial for metastatic melanoma. As of December 31, 2021, Evaxion had cash and cash equivalents totaling $32.2 million, ensuring operational funding for at least 12 months. The firm has also received Australian clearance for its clinical trial and achieved significant clinical milestones, underlining its commitment to innovation in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced key management additions: Bo Karmark as Chief Financial Officer and Jesper Nyegaard Nissen as Chief Operating Officer. Both bring over 25 years of experience in the biotech and pharmaceutical sectors, expected to enhance Evaxion's growth and clinical development efforts. CEO Lars Wegner expressed confidence in their capabilities to advance the company’s promising pipeline of AI-powered immunotherapies for cancer and infectious diseases. The company's strategy aims to leverage AI for effective drug discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has completed recruitment for its Phase 1/2a clinical trial of EVX-02, targeting adjuvant melanoma patients. The Company aims to prevent tumor relapse post-surgery. Encouraging preliminary findings indicate the treatment is well-tolerated, with no serious side effects reported. The next step is a dedicated Phase 2b trial, expected to begin following the finalization of recruitment. Final data from the current trial will be announced in Q2 2023, earlier than anticipated, with milestones including regulatory filings in H1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced the publication of a paper on its personalized cancer immunotherapy EVX-01 aimed at metastatic melanoma, published in OncoImmunology. The Phase 1/2a trial results indicate that EVX-01 is safe and shows early signs of antitumor activity when combined with standard anti-PD-1 treatment, supported by the company's PIONEER AI technology. The upcoming Phase 2b trial, in collaboration with Merck, is set to begin in Q2 2022, focusing on efficacy and safety in treatment-naïve patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
-
Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) has received Australian Therapeutic Goods Administration clearance to commence a Phase 2b trial for its patient-specific cancer immunotherapy EVX-01, in combination with Merck’s KEYTRUDA®. The trial aims to evaluate the safety and efficacy of this treatment in approximately 100 adults with unresectable or metastatic melanoma, focusing on overall response as the primary endpoint. The study is set to begin in Q2 2022, following promising data from the ongoing Phase 1/2a trial, where EVX-01 demonstrated a 67% benefit rate compared to 40% historical data for the anti-PD-1 therapy alone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has completed its follow-on public offering of 3,942,856 American Depositary Shares (ADSs) at a price of $7.00 per ADS. The offering included the full exercise of the underwriters’ option to purchase an additional 514,285 ADSs, generating approximately $27.6 million in gross proceeds before deductions. The ADSs are traded on the Nasdaq Capital Market. Oppenheimer & Co. Inc. served as the sole book-running manager for this offering, with additional support from Ladenburg Thalmann & Co. Inc. and Lake Street Capital Markets, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Rhea-AI Summary

Evaxion Biotech reported Q3 2021 financial results, highlighting a follow-on public offering (FPO) of 3.9 million ADSs expected to raise $27.6 million. Key developments include positive Phase 1/2a trial results for EVX-01, showing a 67% patient benefit rate in metastatic melanoma, and EVX-02 demonstrating T-cell activation. Cash reserves were $11.9 million, bolstered by the FPO. The company's net loss was $5.3 million, slightly higher than the previous year. Upcoming milestones include Phase 2b trials for EVX-01 and EVX-02 in early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has announced the pricing of a follow-on public offering of 3,428,571 American Depositary Shares (ADSs) at $7.00 each, aiming to raise approximately $24 million before fees. The offering, expected to close on November 9, 2021, includes an option for underwriters to purchase an additional 514,285 ADSs. Oppenheimer & Co. Inc. serves as the book-running manager. Evaxion is focused on developing AI-driven immunotherapies for various diseases, with several candidates in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.64%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (Nasdaq: EVAX) announced the filing of a Registration Statement with the SEC for a proposed follow-on public offering of American Depositary Shares (ADSs). The offering will include an option for underwriters to purchase an additional 15% of the ADSs. The specific details regarding the number and price of shares are yet to be determined. Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are managing the offering, which is subject to market conditions and the Registration Statement's effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.02%
Tags
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has announced a collaboration with Merck & Co. to conduct a Phase 2b clinical trial for its cancer immunotherapy EVX-01 in combination with KEYTRUDA® (pembrolizumab). The trial will focus on patients with metastatic melanoma (stage III and IV) and aims to begin in Q4 2021. Evaxion will lead the study, while Merck provides KEYTRUDA®. Previous promising results from Phase 1/2a trials suggest EVX-01 may enhance melanoma treatment efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
none

FAQ

What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?

The current stock price of Evaxion Biotech A/S American Depositary Share (EVAX) is $0.894767 as of December 24, 2024.

What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?

The market cap of Evaxion Biotech A/S American Depositary Share (EVAX) is approximately 5.2M.

What does Evaxion Biotech A/S specialize in?

Evaxion Biotech A/S specializes in developing novel vaccines and therapies using artificial intelligence to solve significant health challenges.

What are the main AI platforms used by Evaxion Biotech?

Evaxion Biotech uses the PIONEER, EDEN, RAVEN, and ObsERV AI platforms for drug discovery and development.

What are Evaxion's leading product candidates?

Evaxion's leading product candidates include EVX-01 and EVX-02 for cancer treatment and EVX-03 for non-small-cell lung cancer.

What recent developments have taken place at Evaxion Biotech?

Recent developments include a replay of the R&D Day presentations, information about the EVX-01 Phase 2 clinical trial, and a resolution of a Nasdaq equity deficiency issue.

When was Evaxion Biotech A/S founded?

Evaxion Biotech A/S was founded in 2008.

How does the EDEN platform contribute to Evaxion's research?

The EDEN platform aids in the rapid discovery of novel antigens that elicit cross-protective immune responses against bacterial pathogens.

What is PIONEER platform's role in Evaxion's operations?

The PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses, particularly in cancer treatments.

What kind of financial challenges has Evaxion recently addressed?

Evaxion addressed a Nasdaq equity deficiency issue related to the IFRS accounting treatment of investor warrants by converting the exercise price from USD to DKK.

Where can I find more information about Evaxion's recent activities?

More information about Evaxion's recent activities can be found on their official website at www.evaxion-biotech.ai.

What is the mission of Evaxion Biotech A/S?

The mission of Evaxion Biotech A/S is to tackle significant global health challenges using artificial intelligence to develop novel vaccines and immunotherapies.

Evaxion Biotech A/S American Depositary Share

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

5.25M
4.17M
25.25%
9.9%
0.61%
Biotechnology
Healthcare
Link
United States of America
Horsholm